Harrow Health, Inc. 11.875% Senior Notes due 2027
HROWM
NASDAQ Global Market26.03
USD
-0.02
- -
Harrow Health, Inc. 11.875% Senior Notes due 2027
HROWM
(NASDAQ Global Market)
Recent
price
26.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Harrow, Inc. develops, manufactures, and commercializes ophthalmic pharmaceutical products focused on eye care conditions including dry eye disease, glaucoma, cataracts, post-operative inflammation, and retinal diseases such as wet age-related macular degeneration. The company offers a comprehensive portfolio encompassing FDA-approved branded products such as IHEEZO (chloroprocaine HCl ophthalmic gel) for ocular anesthesia in cataract surgery, VEVYE for dry eye disease, and biosimilars including BYOOVIZ, OPUVIZ, and upcoming BYQLOVI; authorized generics; and customized compounded formulations through its subsidiary ImprimisRx, which provides high-volume sterile compounding for ophthalmologists addressing underserved patient needs. Harrow operates primarily in the United States, serving ophthalmologists, surgical centers, and patients through a vertically integrated model that includes sterile manufacturing facilities, with a focus on accessibility, affordability, and clinical outcomes in the ophthalmic healthcare market. Founded in 1998 and headquartered in Nashville, Tennessee, the company, formerly known as Harrow Health, Inc., rebranded to Harrow, Inc. in September 2023 to reflect its expanded ophthalmic focus. In recent developments, Harrow entered into an exclusive U.S. commercialization agreement with Samsung Bioepis in July 2025 for ophthalmology biosimilars BYOOVIZ and OPUVIZ, following Biogen's exit, with BYQLOVI expected to launch commercially in Q4 2025; announced an agreement in September 2025 to acquire Melt Pharmaceuticals, Inc., a clinical-stage firm, to advance MELT-300 as a potential FDA-approved successor to its compounded MKO Melt sedation product, with an NDA planned by 2027; priced a $250 million 8.625% senior notes offering due 2030 in September 2025 to refinance existing debt including the $40.25 million 11.875% Senior Notes due 2027 (HROWM), an Oaktree facility, and HROWL notes, alongside securing a new $40 million revolving credit facility; launched the Harrow Access for All (HAFA) program in September 2025 to cap costs at $59 for over 15 ophthalmic medications, building on the VEVYE Access for All program's success; and expanded VAFA distribution through a partnership with Alto Pharmacy. These initiatives support Harrow's growth trajectory, with Q3 2025 revenue reaching $71.6 million, up 45% year-over-year, and plans for four new product launches over the next three years amid ongoing portfolio diversification beyond compounding.